TOP > 外国特許検索 > THERAPEUTIC AGENT FOR INTRACELLULAR TDP-43 CONTENT-RELATED DISEASE

THERAPEUTIC AGENT FOR INTRACELLULAR TDP-43 CONTENT-RELATED DISEASE

外国特許コード F170009124
整理番号 (S2016-0233-N0)
掲載日 2017年7月13日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2016JP088738
国際公開番号 WO 2017111166
国際出願日 平成28年12月26日(2016.12.26)
国際公開日 平成29年6月29日(2017.6.29)
優先権データ
  • 特願2015-253332 (2015.12.25) JP
発明の名称 (英語) THERAPEUTIC AGENT FOR INTRACELLULAR TDP-43 CONTENT-RELATED DISEASE
発明の概要(英語) According to the present invention, a drug for treating an intracellular TDP-43 content-related disease is developed and provided . In the binding of TDP-43 to a specific mt-tRNA, the binding sites of the respective substances are identified. On the basis of the result of the identification, a binding inhibitor capable of selectively inhibiting the binding of TDP-43 to the specific mt-tRNA is developed.
従来技術、競合技術の概要(英語) BACKGROUND ART
Amyotrophic lateral sclerosis (Amyotrophic Lateral Sclerosis: hereinafter, referred to herein is often 'ALS') is, the brain stem, spinal cord, the motor neuron disorder of upper motor neuron lesions, with the advance of the lower motor neuron disorder, muscle atrophy and muscle weakness associated with the cause of dysfunction of the upper limb movements, gait impairment, dysarthria, dysphagia, disordered breathing such as refractory disease symptoms appear. A relatively long-term survival ventilator also known for the sake of example, of development, normal, relatively fast, average 3.5 years after the onset of paralysis of the respiratory muscles mainly in many cases of mortality.
ALS is one of 5-10%, a family history of familial amyotrophic lateral sclerosis involves Amyotrophic Lateral Sclerosis (familial ALS) called. Familial ALS interrupt is about 2, a free radical scavenging enzyme superoxide dismutase cu/Zn (SOD1: superoxide dismutase 1) (ALS1) reported that mutations in the gene (non-patent document 1) and, ALS 1 SOD1 gene are considered to be one of the causal genes. In addition, as the causal genes other ALS, (non-patent document 2) (angiogenin) , vesicle membrane binding protein (VAMP: vesicle-associated membrane protein) / synaptic vesicle binding protein B(synaptobrevin-associated membrane protein B) (non-patent document 3), 43(TAR DNA-binding protein-43 TAR DNA binding protein: hereinafter, often referred to herein as' TDP-43' referred to) (non-patent document 4), fused in sarcoma/translated in liposarcoma(FUS/TLS) (and non-patent document 5) have been reported such as gene. However, due to the abnormality of these genes, how to develop ALS, or to the progress of the disease state, is known about the specific mechanism is not.
Maruyama et al. (non-patent document 6) is, in the example 6 of the 3 familial ALS patient example, involved in intracellular signaling to suppress NFκB optineurin gene (optineurin) disclosed a variation. Mutant optineurin, leading to a loss of the suppressive activity of NFκB it, ALS NFκB inhibitor is likely to have a therapeutic effect has been suggested. However, the 90-95% of the ALS, sporadic and, in many ALS patients than the optineurin gene, mutated in rather TDP-43 gene has been found. Therefore, even if the inhibitor has an effect in the treatment of ALS NFκB even, its therapeutic effect is, only a small part of ALS can be expected in a patient.
Rothstein et al. (non-patent document 7) is, the mutant SOD1 gene in the patient's cerebrospinal fluid ALS, wild-type SOD1 gene healthy in comparison to glutamic acid (often abbreviated as' Glu ' or less) can be nearly a fourfold increase in the concentration of 3, and the population studies in sporadic ALS spinal Glu 40% of the patients an increase of from each other, along with increase of the fuel-Glu Glu ALS play an important role in the mechanism of development suggests that are responsible for. An increase in a patient such Glu ALS, loss of astrocytes Glu uptake is believed to be the cause. Therefore, poison Glu, in particular glutamate receptor sub-type α - hydroxy -5 - methyl -4 - amino -3 - acid (AMPA) receptor-mediated Glu Glu by toxins neuropathy due to an increase in a result generated, consistent with the hypothesis that the onset of sporadic ALS is promising. For example, in human ALS motor neurons, AMPA receptor subunit RNA editing rate is low and the GluR2 Q/R site, sporadic ALS play an important role in the pathology report to the effect that the (non-patent document 8-12), supporting the hypotheses.
(Non-patent document 13) Lacomblez et al. is, Riluzole ALS (Riluzole) survival of the patient is in a small amount can be significantly extended clinical test results disclosed. Riluzole is, said hypothesis is developed based on the glutamic acid antagonist. At present, only this Riluzole ALS as a therapeutic drug approved in Japan and Europe (trade name: ). However, riluzole is, to suppress an increase in the cause of ALS is not Glu, due to an increase in handling the effect of reducing the poison Glu Glu therapy but only, in the cardinal symptoms of ALS or other muscle weakness is not a validity with respect to clinical symptoms.
Is Patent Document 1, large doses of methylcobalamin ALS (Methylcobalamin) by a certain improvement effect in the clinical symptoms of disclosed is observed, the current, double-blind comparison tests of methylcobalamin has been promoted. However, a glutamate Agent to be mainly cell death inhibitory effect (non-patent document 14) based on, the effect of Riluzole can not be expected to improve. However, a high concentration of methylcobalamin is, by adenosylmethionine S- competitively inhibit methylation of DNA for, high retention become possible gene transcription (non-patent document 15). Therefore, it is necessary for nerve regeneration by promoting the synthesis of the protein, cerebral spinal cord from reaching the movement of the protection of neuronal cells or not, is assumed to be, actually ALS pathology, indicating a relationship of the onset mechanism and there is no evidence, merely generally remains stoichiometric inference.
In addition, a diagnosis of ALS can be confirmed diagnosis to date no specific clinical inspection method, conventionally, medical history and neurological findings totally judgment, onset of diagnosis and accurate diagnosis is difficult.
So far as one of the causal genes ALS, sporadic and familial ALS ALS high mutation frequency in any of the suggested that TDP-43 gene (non-patent document 16-23), further ALS patient lesion cells including TDP-43 cytoplasmic accumulation of the deposits also known (non-patent document 17). However, TDP-43 TDP-43 functions within the cells and the mutation relates to how the onset ALS, the mechanism will be, from the known up to now.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY
  • TOKYO METROPOLITAN UNIVERSITY
  • 発明者(英語)
  • IZUMIKAWA Keiichi
  • TAKAHASHI Nobuhiro
  • ISHIKAWA Hideaki
  • ISOBE Toshiaki
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
※ 国立大学法人東京農工大学では、先端産学連携研究推進センターにおいて、知的財産の創出・権利化・活用に取り組んでいます。上記の特許・技術の内容および導入に興味・関心がありましたら、当センターまでお気軽にお問い合わせください。

PAGE TOP

close
close
close
close
close
close